Articles related to GOUT

SGLT-2 inhibitors offer benefits beyond glucose control, potentially addressing the systemic inflammatory components of metabolic diseases like diabetes, heart failure, and gout.

Explore the study’s analysis, which also uncovers potential cardiovascular benefits associated with SGLT2i initiation among patients with gout and type 2 diabetes.

With the resurgence of gout in individuals over 30, it’s important to recognize its primary triggers and symptoms for early diagnosis and management, ensuring this treatable form of arthritis doesn’t lead to long-term damage in patients.

In contradistinction to recent reports that showed increased risk of death and no clinical benefit with escalation of allopurinol for progressive CKD, this 5-year population-based review found no increased mortality risk in escalating allopurinol dose and achieving target serum urate levels.